A week after Purdue Pharma and the Sackler family agreed to a $7.4 billion settlement over lawsuits related to the opioid painkiller OxyContin, the FDA approved Vertex’s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years—potentially reshaping the treatment landscape.
Marketed as JOURNAVX, suzetrigine is a groundbreaking non-opioid pain reliever designed to manage moderate to severe acute pain in adults. As an oral voltage-gated sodium channel (NaV) inhibitor, it blocks pain signals in the peripheral nervous system before they reach the brain. This approval represents the most significant pain management advancement in ...
